Continue Xarelto with Close Monitoring
In this 69-year-old woman with history of PE/DVT on rivaroxaban who develops a subconjunctival hemorrhage, it is safe to continue anticoagulation without interruption. Subconjunctival hemorrhage is a minor, self-limited bleeding event that does not warrant discontinuation of life-saving anticoagulation in a patient with recurrent VTE.
Rationale for Continuing Anticoagulation
This patient has high thrombotic risk given her history of both PE and DVT, which qualifies as recurrent VTE. According to ESC guidelines, patients with recurrent VTE (at least one previous episode of PE or DVT) not related to a transient/reversible risk factor should continue oral anticoagulation indefinitely 1. The 2021 CHEST guidelines similarly recommend extended-phase anticoagulation for unprovoked or recurrent VTE 2.
Stopping anticoagulation in this patient would expose her to substantial risk of recurrent, potentially fatal PE. The thrombotic risk far outweighs the minimal risk posed by a subconjunctival hemorrhage.
Understanding Subconjunctival Hemorrhage on Anticoagulation
Subconjunctival hemorrhage is:
- Not a major bleeding event by any clinical definition
- Self-limited and resolves spontaneously within 1-2 weeks
- Does not threaten vision or organ function
- Common even in patients not on anticoagulation
- Not a contraindication to continuing anticoagulation
The 2020 ACC Expert Consensus on bleeding management does not classify subconjunctival hemorrhage as major bleeding requiring anticoagulation interruption 3. Major bleeding is defined as bleeding that is life-threatening, involves critical organs (intracranial, intraspinal, intraocular with vision compromise, pericardial), or causes hemodynamic instability.
Monitoring Considerations
While continuing rivaroxaban:
Assess for other bleeding manifestations:
- Gingival bleeding
- Gastrointestinal bleeding (melena, hematochezia, hematemesis)
- Hematuria
- Easy bruising beyond baseline
- Epistaxis that is prolonged or difficult to control
Check baseline labs if not recently done:
- Complete blood count (hemoglobin/hematocrit, platelet count)
- Creatinine clearance (rivaroxaban is renally cleared; dose adjustment needed if CrCl 15-50 mL/min) 4, 5
- Liver function tests
Review medication interactions:
- Strong CYP3A4 inhibitors (azole antifungals, HIV protease inhibitors, clarithromycin) increase rivaroxaban levels
- P-glycoprotein inhibitors also increase exposure 6
When to Consider Dose Adjustment
The standard VTE treatment dose of rivaroxaban is 15 mg twice daily for 21 days, then 20 mg once daily 4, 7.
Consider dose reduction to 15 mg once daily if:
- CrCl 30-49 mL/min 7, 5
- Age >75 years with additional bleeding risk factors
- Weight <50 kg
- Concomitant antiplatelet therapy
However, do not empirically reduce the dose based solely on subconjunctival hemorrhage, as this minor bleeding does not indicate systemic over-anticoagulation.
Red Flags Requiring Anticoagulation Interruption
Stop rivaroxaban immediately and seek urgent evaluation if:
- Major bleeding: Hemodynamic instability, drop in hemoglobin >2 g/dL, transfusion requirement
- Critical site bleeding: Intracranial, intraspinal, intraocular (with vision changes), retroperitoneal, pericardial
- Uncontrolled bleeding despite local measures
The French perioperative guidelines note that routine coagulation monitoring is not needed for DOACs when used at standard doses with appropriate discontinuation intervals 7.
Common Pitfalls to Avoid
Do not:
- Discontinue anticoagulation for isolated subconjunctival hemorrhage
- Order routine coagulation studies (PT/INR, aPTT) as these are not reliable for monitoring rivaroxaban
- Switch to warfarin or LMWH unnecessarily, as this increases complexity without improving safety
- Reduce the rivaroxaban dose below therapeutic levels, which would expose the patient to recurrent VTE risk
Do:
- Reassure the patient that subconjunctival hemorrhage is benign and expected to resolve
- Document the event and continue current therapy
- Ensure the patient understands warning signs of major bleeding
- Verify renal function is adequate for current dosing
The evidence consistently shows that rivaroxaban is effective and safe for VTE treatment in elderly patients, with acceptable bleeding rates in real-world registries 8, 9, 10, 11.